Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Existing guidelines acknowledge the risks of overdiagnosis and overtreatment associated with early detection of prostate cancer and breast cancer and recommend against screening for these tumors in individuals with limited life expectancy.1,2 The cost to the US health care system related to overdiagnosis may be as high as $1.2 billion annually.3 That finding, combined with the aging population and an expected surge of older individuals with prostate cancer and breast cancer in upcoming years,4 indicates that a contemporary nationwide and state-by-state assessment of the prevalence of nonrecommended screening for prostate cancer and breast cancer is essential and timely.
Abdollah F, Sun M, Sammon JD, Choueiri TK, Menon M, Weissman JS, Trinh Q. Prevalence of Nonrecommended Screening for Prostate Cancer and Breast Cancer in the United StatesA Nationwide Survey Analysis. JAMA Oncol. 2016;2(4):543-545. doi:10.1001/jamaoncol.2015.5871